The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVO.L Regulatory News (AVO)

  • There is currently no data for AVO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FORM 8.3 - Advanced Oncotherapy

5 May 2023 08:56

RNS Number : 5667Y
Celeste Management SA
05 May 2023
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Celeste Management SA

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Louis Dreyfus family members

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Advanced Oncotherapy

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

02 May 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

25 P ordinary

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

30,333,333

5.64%

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

30,333,333

5,64%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

warrants

Details, including nature of the rights concerned and relevant percentages:

We hold:

· AVO WARRANT 25P 17 APR 2026: 1,200,000

· AVO WARRANT 25P 01 JUL 2026: 800,000

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

none

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

none

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

03/05/2023

Contact name:

Dimitri Boulanger

Telephone number*:

+41228001488

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETAAMRTMTBMMFJ
Date   Source Headline
25th Apr 20139:34 amRNSDirector Dealing
24th Apr 20137:00 amRNSIssue of Equity
24th Apr 20137:00 amRNSProposed Acquisition of ADAM S.A, a CERN Spin Off
22nd Apr 20137:00 amRNSFirst UK Customers for IORT Treatment
11th Apr 20134:48 pmRNSCollaboration Announcement
11th Apr 20134:44 pmRNSCollaboration Announcement
8th Apr 20137:00 amRNSAppointment of Director
18th Mar 20137:00 amRNSDirectorate Change
18th Feb 20137:00 amRNSPotential Acquisition
15th Jan 201312:17 pmRNSDisposal
21st Dec 20123:54 pmRNSResult of EGM
5th Dec 20126:10 pmRNSSale of subsidiary, Notice of Meeting
5th Nov 20127:00 amRNSPlacing to raise £0.35 million with AB Segulah
28th Sep 201211:55 amRNSHalf Yearly Report
20th Sep 20123:21 pmRNSIssue of Equity
7th Sep 20121:33 pmRNSChange of Name
31st Aug 20121:03 pmRNSResult of GM
8th Aug 20123:15 pmRNSNotice of AGM
1st Aug 20127:00 amRNSIssue of Equity
16th Jul 20127:00 amRNSProposed Demerger
5th Jul 20123:26 pmRNSIssue of Equity
29th Jun 20121:16 pmRNSFinal Results
28th Jun 20127:00 amRNSAppointment of Director
12th Jun 20127:00 amRNSAgreement with Varigen Technologies
11th Jun 20122:24 pmRNSHolding(s) in Company
8th Jun 201212:48 pmRNSHolding(s) in Company
8th Jun 20127:00 amRNSMarketing & Business Development Appointment
18th May 20125:26 pmRNSIssue of Equity
3rd May 20123:45 pmRNSHolding(s) in Company
3rd May 20123:45 pmRNSHolding(s) in Company
20th Apr 20121:03 pmRNSChange of Registered Office
19th Apr 20127:00 amRNSFolkestone Women's Health Project
28th Mar 20127:00 amRNSRestructuring, Proposed Change of Name, etc
26th Mar 20126:05 pmRNSHolding(s) in Company
22nd Mar 201210:59 amRNSHolding(s) in Company
13th Mar 20127:05 amRNSOncotherapy Resources Limited
28th Feb 20122:23 pmRNSAdmission Date and Total Voting Rights
27th Feb 20127:00 amRNSPlacing and Directors' Shareholdings
14th Feb 20127:00 amRNSCompletion of Medical Centre Development
31st Jan 20123:24 pmRNSResult of AGM
31st Jan 20127:00 amRNSAGM Trading Update
16th Jan 20124:34 pmRNSHolding in Company
21st Dec 20111:00 pmRNSRestoration - CareCapital Group plc
21st Dec 201112:36 pmRNSStatement re. Suspension
21st Dec 20119:17 amRNSHalf Yearly Report
21st Dec 20119:17 amRNSFinal results & notice of AGM
16th Dec 20114:58 pmRNSDirectorate Change
19th Sep 201111:45 amRNSResult of EGM
8th Sep 20112:41 pmRNSResolution to grant plannning permission
1st Sep 20114:23 pmRNSNotice of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.